Hypermobility in Patients with Chronic Fatigue Syndrome: Preliminary Observations

REFERENCES

• Bombardier C H, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia. Disability and health care use. Med Care 1996; 34: 924–30
   PubMed Web of Science ®Google Scholar
• Goldenberg D L. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1991; 3: 247–258
   PubMedGoogle Scholar
• Klimas N, Salvato F, Morgan R, Fletcher M A. Immunological abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403–1410
   PubMed Web of Science ®Google Scholar
• Hudson N, Starr M R, Esdaile J M, Fitzcharles M-A. Diagnostic associations with hypermobility in rheumatology patients. Br J Rheumatol 1995; 34: 1157–1161
   PubMedGoogle Scholar
• Karaaslan Y, Haznedaroglu S, Öztürk M. Joint hypermobility and primary fibromyalgia: A clinical enigma. J Rheumatol 2000; 27: 1774–6
   PubMed Web of Science ®Google Scholar
• Norton P A, Baker J E, Sharp H C, Warenski J C. Genitourinary prolapse and joint hypermobility in women. Obstet Gynecol 1995; 85: 225–228
   PubMed Web of Science ®Google Scholar
• Seow C C, Chow P K, Khong K S. A study of joint mobility in a normal population. Ann Acad Med Singapore 1999; 28: 231–6
   PubMedGoogle Scholar
• Rowe P C, Barron D F, Calkins H, Maumenee I H, Tong P Y, Geraghty M T. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135: 494–9
   PubMed Web of Science ®Google Scholar
• Gannon L M, Bird H A. The quantification of joint laxity in dancers and gymnasts. J Sports Sci 1999; 17: 743–50
   PubMed Web of Science ®Google Scholar
• Hall M G, Ferrell W R, Sturrock R D, Hamblen D L, Baxendale R H. The effect of the hypermobility syndrome on knee joint proprioception. Br J Rheumatol 1995; 34: 121–125
   PubMedGoogle Scholar
• Mallik A K, Ferrell W R, McDonald A G, Sturrock R D. Impaired proprioceptive acuity at the proximal interphalangeal joint in patients with the hypermobility syndrome. Br J Rheumatol 1994; 33: 631–637
   PubMedGoogle Scholar
• Fitzcharles M-A. Is hypermobility a factor in fibromyalgia?. J Rheumatol 2000; 27: 1587–1589
   PubMed Web of Science ®Google Scholar
• Lai S, Goldman J A, Child A H, Engel A, Lamm S H. Fibromyalgia, hypermobility, and breast implants. J Rheumatol 2000; 27: 2237–41
   PubMed Web of Science ®Google Scholar
• Gedalia A, Press J, Klein M, Buskila D. Joint Hypermobility and fibromyalgia in schoolchildren. Ann Rheum Dis 1993; 52: 494–496
   PubMed Web of Science ®Google Scholar
• Barrow D F, Cohen B A, Geraghty M T, Violand R, Rowe P C. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. J Pediatr 2002; 141: 421–5
   PubMed Web of Science ®Google Scholar
• Beighton P H, Solomon L, Soskolne C L. Articular mobility in an African population. Ann Rheum Dis 1973; 32: 413–7
   PubMed Web of Science ®Google Scholar
• Fukuda K, Strauss S E, Hickie I, Sharpe M C, Dobbins J G, Komaroff A, International Chronic Fatigue Syndrome Study Group. The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953–959
   PubMed Web of Science ®Google Scholar
• Nishikai M, Tomomatsu S, Hankins R W, Takagi S, Miyachi K, Kosaka S, Akiya K. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: A possible marker for hypersomnia and cognitive disorders. Rheumatology 2001; 40: 806–810
   PubMed Web of Science ®Google Scholar
• Tan E M, Sugura K, Gupta S. The case definition of chronic fatigue syndrome. J Clin Immunol 2002; 22: 8–12
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, Tugwell P, Campbell S M, Abeles M, Clark P, Fam A G, Farber S J, Fiechtner J J, Franklin C M, Gatter R A, Hamaty D, Lessard J, Lichtbroun A S, Masi A T, McCain G A, Reynolds W J, Romano T J, Russell I J, Sheon R P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Hudson N, Fitzcharles M A, Cohen M, Starr M R, Esdaile J M. The association of soft-tissue rheumatism and hypermobility. Br J Rheumatol 1998; 37: 382–6
   PubMedGoogle Scholar
• Grahame R. Joint hypermobility and genetic collagen disorders: Are they related?. Arch Dis Child 1999; 80: 188–191
   PubMed Web of Science ®Google Scholar
• Carter C, Wilkinson J. Persistent joint laxity and congenital dislocation of the hip. J Bone Joint Surg 1964; 46: 40–45
   Web of Science ®Google Scholar
• De Meirleir K, Peterson D L, De Becker P, Englebienne P. From laboratory to patient care; Chronic fatigue Syndrome: A biological approach, P Englebienne, K De Meirleir. CRC Press, Boca Raton 2002; 265–284
   Google Scholar
• Nijs J, Vaes P, McGregor N, Van Hoof E, De Meirleir K. Activity limitations and participation restrictions in patients with chronic fatigue syndrome—Construction of a disease specific questionnaire. J Chronic Fatigue Syndr 2002; 10: 3–23
   Google Scholar
• Nijs J, Vaes P, McGregor N, Van Hoof E, De Meirleir K. Psychometric properties of the Dutch Chronic Fatigue Syndrome Activities and Participation Questionnaire (CFS-APQ). Phys Ther 2003; 83: 444–454
   PubMed Web of Science ®Google Scholar
• Anderson J S, Ferrans C E. The quality of life of persons with chronic fatigue syndrome. J Nerv Ment Dis 1997; 185: 359–367
   PubMed Web of Science ®Google Scholar
• Harms-Ringdahl K, Carlsson A M, Ekholm J, Raustorp A, Svensson T, Toresson H G. Pain assessment with different intensity scales in response to loading joint structures. Pain 1986; 27: 401–412
   PubMed Web of Science ®Google Scholar
• Jensen M D, Koroly P, Braver S. The measurement of clinical pain intensity: A comparison of six methods. Pain 1986; 27: 117–126
   PubMed Web of Science ®Google Scholar
• Bulbena A, Duró J C, Porta M, Faus S, Vallescar R, Martín-Santos R. Clinical assessment of hypermobility of joints: Assembling criteria. J Rheumatol 1992; 19: 115–122
   PubMed Web of Science ®Google Scholar
• Portney L G, Watkins M P. Foundations of clinical research—applications to practice (second ed). Prentice Hall Health, New Jersey 2000; 475–8
   Google Scholar
• Fritz J M, Wainner R S. Examining diagnostic tests: An evidence-based perspective. Phys Ther 2001; 81: 1546–1564
   PubMed Web of Science ®Google Scholar
• Acususo-Diaz M, Collantes-Estevez E. Joint hypermobility in patients with fibromyalgia syndrome. Arthritis Care Res 1998; 11: 39–42
   PubMed Web of Science ®Google Scholar
• Jessee E F, Owen D S, Jr., Sagar K B. The benign hypermobility joint syndrome. Arthritis Rheum 1980; 23: 1053–6
   PubMed Web of Science ®Google Scholar
• Donnay A, Ziem G. Prevalence and overlap of chronic fatigue syndrome and fibromyalgia syndrome among 100 new patients with multiple chemical sensitivity syndrome. J Chronic Fatigue Syndr 1999; 5: 71–80
   Google Scholar
• Wolfe F, Ross K, Anderson J, Russell I J, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28
   PubMed Web of Science ®Google Scholar
• Goldenberg D L, Silmms R W, Geiger A, Komaroff A L. High frequency of fibromyalgia in patients with chronic fatigue seen in primary care practice. Arthritis Rheum 1990; 33: 381–387
   PubMed Web of Science ®Google Scholar
• De Meirleir K, Bisbal C, Campine I, De Becker P, Salehzada T, Demettre E, Lebleu B. A 37-kDa 2–5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108: 99–105
   PubMed Web of Science ®Google Scholar
• Snell C R, Vanness J M, Strayer D R, Stevens S R. Physical performance and prediction of 2–5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 2002; 16: 107–9
   PubMed Web of Science ®Google Scholar
• Suhadolnik R J, Reichenbach N L, Hitzges P, Sobol R W, Peterson D L, Henry B, Ablashi D V, Müller W EG, Schröder H C, Carter W A, Strayer D R. Upregulation of the 2–5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl)96–104
   Google Scholar
• Engelbienne P, De Meirleir K. Chronic fatigue Syndrome: A biological approach. CRC Press, Boca Raton 2002
   Google Scholar
• Demettre E, Bastide L, D'Haese A, De Smet K, De Meirleir K, Tiev K P, Englebienne P, Lebleu B. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002; 277: 35746–35751
   PubMed Web of Science ®Google Scholar
• Yuan H, Kononov S, Cavalcante F SA, Lutchen K R, Ingenito E P, Suki B. Effects of collagenase and elastase on the mechanical properties of lung tissue strips. J Appl Physiol 2000; 89: 3–14
   PubMed Web of Science ®Google Scholar
• Gigante A, Chillemi C, Greco F. Changes of elastic fibers in musculoskeletal tissues of Marfan syndrome: A possible mechanism of joint laxity and skeletal overgrowth. J Pediatr Orthop 1999; 19: 283–8
   PubMed Web of Science ®Google Scholar
• Nasralla M, Haier J, Nicolson G L. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome. Eur J Clin Microbiol Infect Dis 1999; 18: 859–865
   PubMed Web of Science ®Google Scholar
• Vojdani A, Choppa P C, Tagle C, Andrin R, Samini B, Lapp C W. Detection of Mycoplasma genus, Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol 1998; 22: 355–365
   PubMed Web of Science ®Google Scholar
• Nijs J, Nicolson G L, De Becker P, Coomans D, De Meirleir K. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 2002; 34: 209–214
   PubMed Web of Science ®Google Scholar
• Baseman J, Tully J. Mycoplasmas: Sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 1997; 3: 21–32
   PubMed Web of Science ®Google Scholar
• Baum S C. Mycoplasma pneumoniae and atypical pneumonia, Principles and practice of infectious diseases, G L Mandell, J E Bennet, R Dolin. Churchill Livingstone, New York 1995; 1713–1718
   Google Scholar
• Peterszegi G, Texier S, Robert L. Cell death by overload of the elastin-laminin receptor on human activated lymphocytes: Protection by lactose and melibiose. Eur J Clin Invest 1999; 29: 166–172
   PubMed Web of Science ®Google Scholar
• Dabbagh K, Laurent G J, Shock A, Leoni P, Papakrivopoulou J, Chambers R C. Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol 2001; 186: 73–81
   PubMed Web of Science ®Google Scholar
• De Meirleir K, De Becker P, Nijs J, Peterson D, Nicolson G, Patarca-Montero R, Englebienne P. CFS etiology the immune system, and infection; Chronic fatigue Syndrome: A biological approach, P Englebienne, K De Meirleir. CRC Press, Boca Raton 2002; 201–228
   Google Scholar